CN111803635B - 小分子抑制剂在治疗呼吸道病毒性肺炎上的应用 - Google Patents
小分子抑制剂在治疗呼吸道病毒性肺炎上的应用 Download PDFInfo
- Publication number
- CN111803635B CN111803635B CN202010701456.6A CN202010701456A CN111803635B CN 111803635 B CN111803635 B CN 111803635B CN 202010701456 A CN202010701456 A CN 202010701456A CN 111803635 B CN111803635 B CN 111803635B
- Authority
- CN
- China
- Prior art keywords
- virus
- ahr
- ifn
- viral pneumonia
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003112 inhibitor Substances 0.000 title claims abstract description 52
- 206010035737 Pneumonia viral Diseases 0.000 title claims abstract description 28
- 208000009421 viral pneumonia Diseases 0.000 title claims abstract description 28
- 230000000241 respiratory effect Effects 0.000 title abstract description 10
- 150000003384 small molecules Chemical class 0.000 title abstract description 3
- 241000700605 Viruses Species 0.000 claims abstract description 18
- 239000003814 drug Substances 0.000 claims abstract description 17
- 210000003097 mucus Anatomy 0.000 claims abstract description 11
- LKTNEXPODAWWFM-UHFFFAOYSA-N 2-methyl-N-[2-methyl-4-(2-methylphenyl)azophenyl]-3-pyrazolecarboxamide Chemical group CC1=CC=CC=C1N=NC(C=C1C)=CC=C1NC(=O)C1=CC=NN1C LKTNEXPODAWWFM-UHFFFAOYSA-N 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 14
- 241001678559 COVID-19 virus Species 0.000 claims description 12
- 210000002345 respiratory system Anatomy 0.000 claims description 11
- 208000024891 symptom Diseases 0.000 claims description 10
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 7
- 239000008280 blood Substances 0.000 claims description 7
- 210000004369 blood Anatomy 0.000 claims description 7
- 239000001301 oxygen Substances 0.000 claims description 7
- 229910052760 oxygen Inorganic materials 0.000 claims description 7
- 208000028399 Critical Illness Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 230000004083 survival effect Effects 0.000 claims description 5
- 206010038687 Respiratory distress Diseases 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 abstract description 38
- 229940079593 drug Drugs 0.000 abstract description 11
- 230000009385 viral infection Effects 0.000 abstract description 10
- 230000001575 pathological effect Effects 0.000 abstract description 2
- 208000019693 Lung disease Diseases 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 32
- 102000003984 Aryl Hydrocarbon Receptors Human genes 0.000 description 31
- 108090000448 Aryl Hydrocarbon Receptors Proteins 0.000 description 31
- 102100026720 Interferon beta Human genes 0.000 description 21
- 108090000467 Interferon-beta Proteins 0.000 description 21
- 102100037850 Interferon gamma Human genes 0.000 description 18
- 108010074328 Interferon-gamma Proteins 0.000 description 18
- 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 description 18
- 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 description 18
- 206010035664 Pneumonia Diseases 0.000 description 14
- 210000003437 trachea Anatomy 0.000 description 13
- 241000711573 Coronaviridae Species 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 102000015728 Mucins Human genes 0.000 description 9
- 108010063954 Mucins Proteins 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 206010021143 Hypoxia Diseases 0.000 description 8
- 241000699660 Mus musculus Species 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 238000011830 transgenic mouse model Methods 0.000 description 8
- 230000034994 death Effects 0.000 description 7
- 230000003203 everyday effect Effects 0.000 description 7
- 208000025721 COVID-19 Diseases 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 230000004199 lung function Effects 0.000 description 6
- 102000053723 Angiotensin-converting enzyme 2 Human genes 0.000 description 5
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 230000007954 hypoxia Effects 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 230000019491 signal transduction Effects 0.000 description 5
- 208000000059 Dyspnea Diseases 0.000 description 4
- 206010013975 Dyspnoeas Diseases 0.000 description 4
- 101000929928 Homo sapiens Angiotensin-converting enzyme 2 Proteins 0.000 description 4
- 101001054328 Mus musculus Interferon beta Proteins 0.000 description 4
- 101001044384 Mus musculus Interferon gamma Proteins 0.000 description 4
- 208000037847 SARS-CoV-2-infection Diseases 0.000 description 4
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 4
- 239000000443 aerosol Substances 0.000 description 4
- 230000003097 anti-respiratory effect Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 102000048657 human ACE2 Human genes 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 230000030648 nucleus localization Effects 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 229930040373 Paraformaldehyde Natural products 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 229960000796 barbital sodium Drugs 0.000 description 3
- FTOAOBMCPZCFFF-UHFFFAOYSA-N barbitone sodium Natural products CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 208000018875 hypoxemia Diseases 0.000 description 3
- 238000011532 immunohistochemical staining Methods 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229920002866 paraformaldehyde Polymers 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- RGHFKWPGWBFQLN-UHFFFAOYSA-M sodium;5,5-diethylpyrimidin-3-ide-2,4,6-trione Chemical compound [Na+].CCC1(CC)C([O-])=NC(=O)NC1=O RGHFKWPGWBFQLN-UHFFFAOYSA-M 0.000 description 3
- ZADWXFSZEAPBJS-SNVBAGLBSA-N (2r)-2-amino-3-(1-methylindol-3-yl)propanoic acid Chemical compound C1=CC=C2N(C)C=C(C[C@@H](N)C(O)=O)C2=C1 ZADWXFSZEAPBJS-SNVBAGLBSA-N 0.000 description 2
- BGFHMYJZJZLMHW-UHFFFAOYSA-N 4-[2-[[2-(1-benzothiophen-3-yl)-9-propan-2-ylpurin-6-yl]amino]ethyl]phenol Chemical compound N1=C(C=2C3=CC=CC=C3SC=2)N=C2N(C(C)C)C=NC2=C1NCCC1=CC=C(O)C=C1 BGFHMYJZJZLMHW-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241000709687 Coxsackievirus Species 0.000 description 2
- 241001466953 Echovirus Species 0.000 description 2
- 241000709661 Enterovirus Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241000893570 Hendra henipavirus Species 0.000 description 2
- 101001037256 Homo sapiens Indoleamine 2,3-dioxygenase 1 Proteins 0.000 description 2
- 241000342334 Human metapneumovirus Species 0.000 description 2
- 102100040061 Indoleamine 2,3-dioxygenase 1 Human genes 0.000 description 2
- 241000712431 Influenza A virus Species 0.000 description 2
- 241000713196 Influenza B virus Species 0.000 description 2
- 241000713297 Influenza C virus Species 0.000 description 2
- 208000029523 Interstitial Lung disease Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical group [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- 241000712079 Measles morbillivirus Species 0.000 description 2
- 208000025370 Middle East respiratory syndrome Diseases 0.000 description 2
- 241000711386 Mumps virus Species 0.000 description 2
- FBKMWOJEPMPVTQ-UHFFFAOYSA-N N'-(3-bromo-4-fluorophenyl)-N-hydroxy-4-[2-(sulfamoylamino)ethylamino]-1,2,5-oxadiazole-3-carboximidamide Chemical compound NS(=O)(=O)NCCNC1=NON=C1C(=NO)NC1=CC=C(F)C(Br)=C1 FBKMWOJEPMPVTQ-UHFFFAOYSA-N 0.000 description 2
- 241000526636 Nipah henipavirus Species 0.000 description 2
- YGACXVRLDHEXKY-WXRXAMBDSA-N O[C@H](C[C@H]1c2c(cccc2F)-c2cncn12)[C@H]1CC[C@H](O)CC1 Chemical compound O[C@H](C[C@H]1c2c(cccc2F)-c2cncn12)[C@H]1CC[C@H](O)CC1 YGACXVRLDHEXKY-WXRXAMBDSA-N 0.000 description 2
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 241000702263 Reovirus sp. Species 0.000 description 2
- 241000725643 Respiratory syncytial virus Species 0.000 description 2
- 241000710799 Rubella virus Species 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 150000003278 haem Chemical class 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 2
- 238000003125 immunofluorescent labeling Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000007923 nasal drop Substances 0.000 description 2
- 229940100662 nasal drops Drugs 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 208000026425 severe pneumonia Diseases 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- YPBKTZBXSBLTDK-PKNBQFBNSA-N (3e)-3-[(3-bromo-4-fluoroanilino)-nitrosomethylidene]-4-[2-(sulfamoylamino)ethylamino]-1,2,5-oxadiazole Chemical compound NS(=O)(=O)NCCNC1=NON\C1=C(N=O)/NC1=CC=C(F)C(Br)=C1 YPBKTZBXSBLTDK-PKNBQFBNSA-N 0.000 description 1
- JMYNPQVCVQVODQ-OWOJBTEDSA-N 1,3-dichloro-5-[(e)-2-(4-chlorophenyl)ethenyl]benzene Chemical compound C1=CC(Cl)=CC=C1\C=C\C1=CC(Cl)=CC(Cl)=C1 JMYNPQVCVQVODQ-OWOJBTEDSA-N 0.000 description 1
- CJNMMPAEIYFQIJ-UHFFFAOYSA-N 1-[2-[bis(2-methylpropyl)amino]-5-[2-(2h-tetrazol-5-yl)phenyl]phenyl]-3-(4-methylphenyl)urea Chemical compound CC(C)CN(CC(C)C)C1=CC=C(C=2C(=CC=CC=2)C2=NNN=N2)C=C1NC(=O)NC1=CC=C(C)C=C1 CJNMMPAEIYFQIJ-UHFFFAOYSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- MXKLDYKORJEOPR-UHFFFAOYSA-N 3-(5-fluoro-1h-indol-3-yl)pyrrolidine-2,5-dione Chemical compound C12=CC(F)=CC=C2NC=C1C1CC(=O)NC1=O MXKLDYKORJEOPR-UHFFFAOYSA-N 0.000 description 1
- RFGRNBWAUZSMBN-LBPRGKRZSA-N 6-(4-chlorophenyl)-2-(3-fluorophenyl)-N-[(2S)-1-hydroxypropan-2-yl]-3-oxopyridazine-4-carboxamide Chemical compound ClC1=CC=C(C=C1)C=1C=C(C(N(N=1)C1=CC(=CC=C1)F)=O)C(=O)N[C@H](CO)C RFGRNBWAUZSMBN-LBPRGKRZSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- 208000001528 Coronaviridae Infections Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 1
- 206010053159 Organ failure Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 101001037255 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Indoleamine 2,3-dioxygenase Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- VFMMPHCGEFXGIP-UHFFFAOYSA-N alpha-Naphthoflavone Natural products O1C2=C3C=CC=CC3=CC=C2C(=O)C=C1C1=CC=CC=C1 VFMMPHCGEFXGIP-UHFFFAOYSA-N 0.000 description 1
- 210000002821 alveolar epithelial cell Anatomy 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000013404 behavioral symptom Diseases 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000001680 brushing effect Effects 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000007711 cytoplasmic localization Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229950006370 epacadostat Drugs 0.000 description 1
- UEKKREMMIOJMRO-RUZDIDTESA-O exiguamine A Chemical compound O=C1N(C)C(=O)N(C)[C@@]11C(C(=O)C2=C(NC=C2CCN)C2=O)=C2C2=C(CC[N+]3(C)C)C3=CC(O)=C2O1 UEKKREMMIOJMRO-RUZDIDTESA-O 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000004868 gas analysis Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000002134 immunopathologic effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000010468 interferon response Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 1
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 238000013123 lung function test Methods 0.000 description 1
- 238000005399 mechanical ventilation Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- ABXIUYMKZDZUDC-UHFFFAOYSA-N n-[2-(1h-indol-3-yl)ethyl]-2-(5-methylpyridin-3-yl)-9-propan-2-ylpurin-6-amine Chemical compound N1=C2N(C(C)C)C=NC2=C(NCCC=2C3=CC=CC=C3NC=2)N=C1C1=CN=CC(C)=C1 ABXIUYMKZDZUDC-UHFFFAOYSA-N 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 101150094737 pdm2 gene Proteins 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960002511 phenobarbital sodium Drugs 0.000 description 1
- WRLGYAWRGXKSKG-UHFFFAOYSA-M phenobarbital sodium Chemical compound [Na+].C=1C=CC=CC=1C1(CC)C(=O)NC([O-])=NC1=O WRLGYAWRGXKSKG-UHFFFAOYSA-M 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 150000004053 quinones Chemical class 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 230000004202 respiratory function Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- -1 triazole compounds Chemical class 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2020/113478 WO2021253647A1 (fr) | 2020-06-17 | 2020-09-04 | Utilisation d'un inhibiteur de petites molécules dans le traitement de la pneumonie virale respiratoire |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010552732 | 2020-06-17 | ||
| CN2020105527327 | 2020-06-17 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111803635A CN111803635A (zh) | 2020-10-23 |
| CN111803635B true CN111803635B (zh) | 2023-03-14 |
Family
ID=72866544
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010701456.6A Active CN111803635B (zh) | 2020-06-17 | 2020-07-20 | 小分子抑制剂在治疗呼吸道病毒性肺炎上的应用 |
| CN202010919429.6A Active CN113797337B (zh) | 2020-06-17 | 2020-09-04 | 小分子抑制剂在预防及治疗呼吸道病毒性肺炎中的应用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010919429.6A Active CN113797337B (zh) | 2020-06-17 | 2020-09-04 | 小分子抑制剂在预防及治疗呼吸道病毒性肺炎中的应用 |
Country Status (2)
| Country | Link |
|---|---|
| CN (2) | CN111803635B (fr) |
| WO (1) | WO2021253647A1 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118490680B (zh) * | 2023-06-20 | 2025-02-11 | 吉林省西点药业科技发展股份有限公司 | 瑞香素在制备治疗病毒性肺炎的药物中的应用 |
| CN119258221B (zh) * | 2024-12-11 | 2025-04-04 | 吉林大学 | AhR激动剂在制备治疗放射性肺炎药物中的应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103169970A (zh) * | 2011-12-25 | 2013-06-26 | 复旦大学 | 一种治疗病毒性肺炎的药物组合物 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2375647A1 (fr) * | 1999-07-08 | 2001-01-18 | Patrick T. Prendergast | Utilisation de flavones, de coumarines et de composes associes dans le traitement d'infections |
| EP1418164A1 (fr) * | 2002-11-07 | 2004-05-12 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Nouveaux derivés de stilbène et leur utilisation en tant que antagonistes des ligands du recepteur des arylhydrocarbures |
| CN107648216B (zh) * | 2010-07-27 | 2021-03-30 | 波士顿大学管理委员会 | 作为新型癌症疗法的芳烃受体(AhR)调节剂 |
| NO2694640T3 (fr) * | 2011-04-15 | 2018-03-17 | ||
| US9175266B2 (en) * | 2012-07-23 | 2015-11-03 | Gamida Cell Ltd. | Enhancement of natural killer (NK) cell proliferation and activity |
| MX388871B (es) * | 2014-06-27 | 2025-03-20 | Nogra Pharma Ltd | Moduladores del receptor arilo y metodos para elaborar y usar los mismos. |
| EP3193917B9 (fr) * | 2014-09-17 | 2022-02-16 | IO Biotech ApS | Vaccins comprenants la tryptophane 2,3-dioxygénase (tdo) ou des fragments de la tdo |
| GB201417369D0 (en) * | 2014-10-01 | 2014-11-12 | Redx Pharma Ltd | Compounds |
| CN106860471A (zh) * | 2015-12-13 | 2017-06-20 | 复旦大学 | 一种AhR受体蛋白抑制剂在制备抗病毒药物中的用途 |
| US10640499B2 (en) * | 2016-09-02 | 2020-05-05 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
| BR112020004586A2 (pt) * | 2017-09-08 | 2020-09-08 | Insignis Therapeutics, Inc. | métodos para uso da dipivefrina |
| CN111166734A (zh) * | 2020-02-27 | 2020-05-19 | 黄铭 | 萘醌类物质治疗病原性生物引起的肺炎的用途 |
-
2020
- 2020-07-20 CN CN202010701456.6A patent/CN111803635B/zh active Active
- 2020-09-04 CN CN202010919429.6A patent/CN113797337B/zh active Active
- 2020-09-04 WO PCT/CN2020/113478 patent/WO2021253647A1/fr not_active Ceased
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103169970A (zh) * | 2011-12-25 | 2013-06-26 | 复旦大学 | 一种治疗病毒性肺炎的药物组合物 |
Non-Patent Citations (3)
| Title |
|---|
| A potential role for AHR in SARS-CoV-2 pathology;F Giovannoni 等;《Research Square》;20200427;第2页"摘要"，第2页倒数第1段至第3页第3段，第4页第3段 * |
| Indoleamine 2,3-Dioxygenase (IDO) Activity During the Primary Immune Response to Influenza Infection Modifies the Memory T Cell Response to Influenza Challenge;Leo K. Sage 等;《VIRAL IMMUNOLOGY》;20141231;摘要，第113页左栏第4段，第115页左栏"结果" * |
| Murine Coronavirus Infection Activates the Aryl Hydrocarbon Receptor in an Indoleamine 2,3-Dioxygenase-Independent Manner, Contributing to Cytokine Modulation and Proviral TCDD-Inducible-PARP Expression;Matthew E. Grunewald 等;《Journal of Virology》;20200228;摘要，第2页图1说明 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021253647A1 (fr) | 2021-12-23 |
| CN113797337A (zh) | 2021-12-17 |
| CN111803635A (zh) | 2020-10-23 |
| CN113797337B (zh) | 2023-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2524304C2 (ru) | Применение соли ацетилсалициловой кислоты для лечения вирусных инфекций | |
| US20190309021A1 (en) | Composition Comprising a Peptide and an Inhibitor of Viral Neuraminidase | |
| US20130123345A1 (en) | Method of treating a viral infection dysfunction by disrupting an adenosine receptor pathway | |
| JP7359519B2 (ja) | ライノウイルス感染症の予防又は治療のための薬物 | |
| CA2468344A1 (fr) | Methodes et compositions permettant de traiter des lesions de l'epithelium respiratoire | |
| KR20240108337A (ko) | 유행성 rna 바이러스 감염질환의 예방 또는 치료용 약제학적 조성물 | |
| CN111803635B (zh) | 小分子抑制剂在治疗呼吸道病毒性肺炎上的应用 | |
| PT1734987E (pt) | Interfero-beta para teraputica antivrica de doenãas respiratërias | |
| He et al. | C-fiber degeneration enhances alveolar macrophage-mediated IFN-α/β response to respiratory syncytial virus | |
| KR20230018474A (ko) | 급성 호흡 곤란 증후군, 천식, 또는 알러지성 비염을 치료하기 위한 제형 및 방법 | |
| CN108926707B (zh) | Pf4的抗rsv应用 | |
| HK40029346A (en) | Use of a small molecule inhibitor for treatment of respiratory viral pneumonia | |
| HK40029346B (en) | Use of a small molecule inhibitor for treatment of respiratory viral pneumonia | |
| US7871603B2 (en) | Interferon-beta and/or lambda for use in treating rhinovirus infection in the elderly | |
| US11161881B2 (en) | Composition comprising a peptide and an inhibitor of viral neuraminidase | |
| CN102369012B (zh) | 氧化氘用于治疗病毒性呼吸道疾病的用途 | |
| EP4051307B1 (fr) | Peptide pour la prévention ou le traitement du covid-19 | |
| CA2632032C (fr) | Utilisation de l'interferon-beta et/ou de l'interferon-lambda pour traiter les infections a rhinovirus chez les personnes agees | |
| EP3906934B1 (fr) | Application de dalargine pour la prévention d'infections virales des voies respiratoires et la prévention du développement de complications lors d'infections virales des voies respiratoires | |
| CN119112882A (zh) | 苯基吲哚类化合物在治疗发热伴血小板减少综合征病毒感染中的应用 | |
| EA048350B1 (ru) | Применение даларгина для профилактики орви и предотвращения развития осложнений при заболеваниях орви | |
| CN118370749A (zh) | 揪毒素在制备抗甲型流感病毒感染药物中的应用 | |
| LeVine | Bronchiolitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40029346 Country of ref document: HK |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |